Structure via PubChem · Public domain (PubChem)
lonafarnib
Sign in to saveAlso known as SCH 66336, SCH-66336, SCH66336, 4-(2-{4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]piperidin-1-yl}-2-oxoethyl)piperidine-1-carboxamide
Lonafarnib, sold under the brand name Zokinvy, is a medication used to reduce the risk of death due to Hutchinson-Gilford progeria syndrome and for the treatment of certain processing-deficient progeroid laminopathies in people one year of age and older. It is under trial for its use as combination treatment for Hepatitis D Virus.
Key facts
- Drug.Br
- 2
- Drug.Cl
- 1
- Drug.N
- 4
- Drug.O
- 2
- Drug.image
- Lonafarnib.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 200
- Drug.tradename
- Zokinvy
- Drug.DailyMedID
- Lonafarnib
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- A16
- Drug.ATC_suffix
- AX20
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.CAS_number
- 193275-84-2
- Drug.PubChem
- 148195
- Drug.IUPHAR_ligand
- 8024
- Drug.DrugBank
- DB06448
via Wikipedia infobox
Chemical data
- Formula
- C27H31Br2ClN4O2
- Molecular weight
- 638.8 g/mol
- IUPAC name
- 4-[2-[4-[(2R)-6,15-dibromo-13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl]piperidin-1-yl]-2-oxoethyl]piperidine-1-carboxamide
- SMILES
- C1CN(CCC1CC(=O)N2CCC(CC2)[C@@H]3C4=C(CCC5=C3N=CC(=C5)Br)C=C(C=C4Br)Cl)C(=O)N
- InChIKey
- DHMTURDWPRKSOA-RUZDIDTESA-N
- XLogP
- 4.8
- Polar surface area
- 79.5 Ų
- H-bond donors
- 1
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2020
- Admin. routes
- oral
- Indications
- hepatitis D virus infection, chronic myelogenous leukemia, lymphoma, anaplastic astrocytoma
via ChEMBL · EBI
Research
379 papers- Lonafarnib.2012
- Lonafarnib: First Approval.Drugs · 2021
- Lonafarnib Protects Against Muscle Atrophy Induced by Dexamethasone.Journal of cachexia, sarcopenia and muscle · 2025
- Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor.Nature communications · 2024
- Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein.Signal transduction and targeted therapy · 2024
via PubMed
Wikidata facts
- Mass
- 636.0502281119999
Show 7 more facts
- chemical formula
- C₂₇H₃₁Br₂ClN₄O₂
- isomeric SMILES
- C1CN(CCC1CC(=O)N2CCC(CC2)[C@@H]3C4=C(C=C(C=C4CCC5=CC(=CN=C35)Br)Cl)Br)C(=O)N
- canonical SMILES
- C1CN(CCC1CC(=O)N2CCC(CC2)C3C4=C(C=C(C=C4CCC5=CC(=CN=C35)Br)Cl)Br)C(=O)N
- World Health Organisation international non-proprietary name
- lonafarnib
- subject has role
- enzyme inhibitor
- Commons category
- Lonafarnib
- found in taxon
- Dichrostachys cinerea
Sources (2)
via Wikidata · CC0
~11 min read
Encyclopedic overview
15 sectionsContents
- Medical uses
- Contraindications
- History
- Society and culture
- Legal status
- Research
- Hepatitis D
- Cancer
- Mechanism of Action in Cancer
- Clinical Trials and Efficacy
- Monotherapy
- Combination Therapy
- Side Effects and Safety Profile
- References
- External links
{{Infobox drug | drug_name = | INN = | type = | image = Lonafarnib.svg | image_class = skin-invert-image | width = 200 | alt = | caption =
| pronounce = | tradename = Zokinvy | Drugs.com = | MedlinePlus = | licence_CA = | licence_EU = | DailyMedID = Lonafarnib | licence_US = | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = By mouth | class = | ATCvet = | ATC_prefix = A16 | ATC_suffix = AX20 | ATC_supplemental =
Excerpted from Wikipedia’s “lonafarnib” article, available under the CC BY-SA 4.0 licence.